Acceleron Pharma (XLRN) Receives Daily Media Sentiment Rating of 0.12
Press coverage about Acceleron Pharma (NASDAQ:XLRN) has been trending somewhat positive on Wednesday, according to Accern. The research group identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Acceleron Pharma earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.0594108843515 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the headlines that may have effected Accern Sentiment Analysis’s rankings:
- Determination of the 13C/12C Carbon Isotope Ratio in Carbonates and Bicarbonates by 13C NMR Spectroscopy (environmentguru.com)
- Oppenheimer Holdings Weighs in on Acceleron Pharma Inc.’s Q3 2017 Earnings (XLRN) (americanbankingnews.com)
- Acceleron Pharma Inc. (XLRN) Downgraded to Sell at ValuEngine (americanbankingnews.com)
- Acceleron Announces Closing Of Underwriters’ Option To Purchase Additional Shares (thestreet.com)
XLRN has been the subject of a number of research reports. Cann reiterated a “hold” rating on shares of Acceleron Pharma in a research note on Tuesday, June 13th. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Acceleron Pharma in a research note on Tuesday, June 13th. CIBC cut Acceleron Pharma from an “outperform” rating to a “market perform” rating in a research note on Tuesday, June 13th. Morgan Stanley reduced their price objective on Acceleron Pharma from $51.00 to $42.00 and set an “overweight” rating for the company in a research note on Tuesday, June 13th. Finally, FBR & Co set a $63.00 price objective on Acceleron Pharma and gave the company a “buy” rating in a research note on Tuesday, June 13th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. Acceleron Pharma currently has a consensus rating of “Buy” and an average target price of $42.81.
Acceleron Pharma (XLRN) traded down 1.29% on Wednesday, reaching $38.98. The company’s stock had a trading volume of 130,115 shares. Acceleron Pharma has a 52-week low of $23.07 and a 52-week high of $41.69. The firm has a 50-day moving average price of $37.35 and a 200 day moving average price of $32.00. The firm’s market capitalization is $1.72 billion.
Acceleron Pharma (NASDAQ:XLRN) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.12). The business had revenue of $3.10 million for the quarter, compared to the consensus estimate of $3.69 million. Acceleron Pharma had a negative net margin of 724.22% and a negative return on equity of 44.67%. The firm’s revenue was down 3.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.59) EPS. Equities analysts anticipate that Acceleron Pharma will post ($2.68) earnings per share for the current fiscal year.
In other news, CFO Kevin F. Mclaughlin sold 16,000 shares of the business’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $38.41, for a total value of $614,560.00. Following the sale, the chief financial officer now owns 50,810 shares of the company’s stock, valued at approximately $1,951,612.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Ravindra Kumar sold 13,065 shares of the business’s stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $35.41, for a total value of $462,631.65. Following the completion of the sale, the senior vice president now directly owns 108,392 shares in the company, valued at approximately $3,838,160.72. The disclosure for this sale can be found here. Insiders have sold a total of 66,578 shares of company stock worth $2,518,117 in the last ninety days. 3.90% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: “Acceleron Pharma (XLRN) Receives Daily Media Sentiment Rating of 0.12” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/10/11/acceleron-pharma-xlrn-receives-daily-media-sentiment-rating-of-0-12.html.
Acceleron Pharma Company Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Stock Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related stocks with our FREE daily email newsletter.